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The self-controlled case series method assumes that adverse outcomes arise according to a non-homogeneous
Poisson process. This implies that it is applicable to independent recurrent outcomes. However, the self-
controlled case series method may also be applied to unique, non-recurrent outcomes or first outcomes only,
in the limit where these become rare. We investigate this rare outcome assumption when the self-controlled
case series method is applied to non-recurrent outcomes. We study this requirement analytically and by sim-
ulation, and quantify what is meant by ‘rare’ in this context. In simulations we also apply the self-controlled
risk interval design, a special case of the self-controlled case series design. To illustrate, we extract data
on the incidence rate of some recurrent and non-recurrent outcomes within a defined study population to
check whether outcomes are sufficiently rare for the rare outcome assumption to hold when applying the
self-controlled case series method to first or unique outcomes.
The main findings are that the relative bias should be no more than 5% when the cumulative incidence
over total time observed is less than 0.1 per individual. Inclusion of age (or calendar time) effects will
further reduce bias. Designs that begin observation with exposure maximise bias, whereas little or no bias
will be apparent when there is no time trend in the distribution of exposures, or when exposure is central
within time observed.
Key words: Self controlled case series; Rare events; Poisson process
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http://dx.doi.org/10.1022/bimj.XXXXXXX (please delete if not applicable)
1 Introduction
The self-controlled case series (SCCS) method is a epidemiological study design for investigating the
temporal association between a time-varying exposure and an adverse health outcome (Farrington, 1995;
Whitaker et al., 2006; Petersen et al., 2016). Clearly defined dates must be available for both outcomes
and windows of time that are hypothesized to be at increased risk due to exposure, thus the SCCS method
is best suited to abrupt-onset outcomes and transient exposures, though it can also be used for progres-
sive conditions and indefinite exposures in some circumstances. Its main area of application to date has
been in the study of adverse outcomes following vaccination (Weldeselassie et al., 2011), though it has
also been applied more widely, for example to study the safety of prescription medications (Gault et al.,
2017; Nordmann et al., 2012; Ryan et al., 2012), and to investigate infections as triggers of cardiovascular
outcomes.
The main advantages are that it requires only cases, those who have experienced the outcome of interest,
and is self-controlled, so that any fixed confounders such as sex and ethnicity are automatically controlled
for. However, the SCCS method makes some strong assumptions (Whitaker et al., 2018). The SCCS
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method is unusual amongst epidemiological study designs in that it uses time after an adverse outcome has
occurred. The main limiting assumption is that outcomes must not influence subsequent exposure during
time under observation in the study, nor must outcomes influence time under observation. Further assump-
tions are that time-varying covariates act mutliplicatively on the baseline incidence and that outcomes arise
according a non-homogeneous Poisson process or are non-recurrent and rare. It is this last assumption that
we investigate further here, though other assumptions do bear some influence on our findings.
The SCCS method is derived from a model similar to a cohort study in which outcomes arise according
to a non-homogeneous Poisson process, by conditioning on the total number of outcomes experienced by
each individual. The Poisson assumption implies that the outcomes are potentially recurrent. However, the
method also applies to non-recurrent outcomes, in the limit where these become rare (Farrington, 1995;
Farrington andWhitaker, 2006). The aim of this paper is to quantify what is meant by ‘rare’ in this context,
which we investigate both analytically in a simple scenario and by simulation.
In simulations we apply both the self-controlled case series (SCCS) and self-controlled risk interval
(SCRI) designs. The self-controlled risk interval design is a special case of the SCCS design in which
the total time under observation is cut down to a narrower interval defined in relation to exposure times.
In Section 2 we present the key features of the SCCS method, including the SCCS likelihood and design
choices, including the SCRI design. Section 3 contains some analytical results in simple scenarios to
quantify the asymptotic bias involved when the SCCS method is applied to non-recurrent outcomes. In
Section 4 we present simulations. Section 5 contains some examples of outcome incidence rates.
2 Self-controlled case series (SCCS) method and designs
In this section, we begin by introducing the likelihood for the SCCS model with categorical exposure and
age effects, which we refer to as the ‘standard’ SCCS model. We then distinguish the self-controlled risk
interval (SCRI) design as a special case within the broader class of SCCS designs. We outline a simple
adaptation of SCCS designs to circumvent issues with outcomes changing the probability of exposure. We
then end this section by briefly outlining how bias arises when non-recurrent outcomes are not sufficiently
rare, and how this depends upon the distribution of exposures within the time under observation.
2.1 The standard SCCS likelihood
Suppose that individuals in a given cohort are followed up during observation periods (ai, bi], for the
occurrence of an adverse health outcome of interest. Each individual i included in a case series experiences
ni ≥ 1 outcomes over this observation period, i = 1, ..., N . In a standard SCCS design, exposure status is
categorical and assigned to time windows of hypothesized excess risk due to exposure known as exposure
risk windows, of which there may be several to capture dose, washout periods or varying risk with time
since first exposure, denoted k = 1, ...,K . All other time within an observation period, but outside an
exposure risk window, constitute baseline or reference windows, denoted k = 0.
During their observation period, individual i’s outcome incidence rate is modified by age (or calendar
time) group, exposure risk group, and fixed factors specific to him or her. In a standard SCCS design, age
(or time / season) is divided into categories j = 1, 2, ..., J . We assume that these influences are captured
by the following multiplicative incidence model:
λijk = exp(φi + αj + βk),
where φi represents the combined effect of individual-specific factors, αj is the effect of age in age group
j (or calendar time, as required), assumed to be common to all individuals in the cohort, and βk is the log
relative incidence associated with exposure risk window k, the parameters of interest.
The SCCS method bases estimation of β on a likelihood that involves only the cases within that cohort,
that is, those individuals that experience one or more outcomes during the observation period. Case imight
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experience ni ≥ 1 outcomes, so the total number of outcomes isM =
∑N
i=1 ni. The SCCS likelihoodmay
be derived from a model for the underlying cohort by conditioning, for each case, on the observation period
(ai, bi], the exposure history up to bi, and the number of outcomes ni experienced within the observation
period. The outcomes nijk for case i occur within age group j and exposure risk window k. The SCCS
likelihood is then
L =
n∏
i=1
∏
jk
(
eijk exp(αj + βk)∑
rs eirs exp(αr + βs)
)nijk
.
Note that the individual-specific term φi has factored out: the method adjusts automatically for time-
invariant random and fixed effects that act multiplicatively on the outcome incidence rate.
Here we focus on the standard model for which piecewise constant age and exposure effects are mod-
elled. The likelihood can be generalised and alternative modelling approaches for both age and exposure
effects are available (Ghebremichael-Weldeselassie et al., 2014; Lee and Carlin, 2014; Farrington and
Whitaker, 2006).
The SCCS method is also valid for non-recurrent outcomes (so ni = 1), in the limit where the baseline
incidence rate for individual i, exp(φi) → 0. In practice this requires outcomes to be uncommon: this
is the rare disease assumption. For further details of this derivation see Farrington (1995); Farrington and
Whitaker (2006).
2.2 Standard SCCS and SCRI designs
Originally, the self-controlled case series design was conceptualized with an observation period defined by
age and/or calendar time boundaries (Farrington, 1995). For vaccine safety studies these will be periods
during which vaccines were in current use and at ages that they are usually administered within the popula-
tion, such as the second year of life for mumps, measles, rubella (MMR) vaccine or an influenza season for
seasonal influenza vaccines. Alternatively, observation periods may reflect the length of a database record.
Observation periods can be long, and to account for the fact that the baseline hazard may change it is often
important to include age effects in the model. Thus, a set up for an SCCS model with an age-defined
observation period is illustrated in figure 1, panel (a)
An alternative is to ascertain exposure histories, and define observation periods in relation to exposure,
thus cutting down observation time used and altogether dropping cases whose outcomes arose further in
time from exposure. This approach is taken for the self-controlled risk interval (SCRI) design (Tse et al.,
2012; Baker et al., 2015), a special case of an SCCS design. In a typical SCRI design, a single exposure
risk window is defined, along with either one or two reference or control windows, before and after the
exposure risk window or following the exposure risk window. Reference windows are not necessarily
contiguous to exposure risk windows, as for example, allowance may need to be made for washout periods
(whereas washout periods would be modelled in the original SCCS design, SCRI simply leaves gaps in
observation time). This is illustrated in figure 1, panel (c).
Age may be dropped from the SCRI model under the assumption that age effects are constant over the
relatively short observation period, though this may not always be reasonable and strategies for control of
age effects in the SCRI model have been outlined by Li et al. (2015).
Much consideration has been given to the main limiting assumption in the family of SCCS designs that
outcomes must not influence subsequent exposure (Whitaker et al., 2006; Petersen et al., 2016; Farrington
et al., 2009; Kuhnert et al., 2011). Short-term influence is often accounted for by including a pre-exposure
window in a SCCS modelling approach, or by including a gap in observation prior to exposure in the
SCRI approach. Long-term or permanent influence is usually more complicated to account for (Farrington
et al., 2009), except when there can only be a single exposure within an observation period, where a
simple strategy is to use only post-exposure time as illustrated in figure 1, panel (b) for SCCS and panel
(d) for SCRI. For example, this design set up can be used when the outcome of interest is death, after
c© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
4 Whitaker et al.: Self-controlled case series studies with common non-recurrent outcomes.
which exposure is impossible, post-death time is included until the planned end of observation (Hubbard
et al., 2005; Petersen et al., 2016). That there should be only a single exposure within each observation
period is more easily met using the SCRI approach which shortens observation time, for example there is
often some minimum interval between vaccine doses. The SCRI approach using a single post-exposure
reference window roughly matches the adapted SCCS method formulated to study the association between
multi-dose vaccinations and death outlined by Kuhnert et al. (2011). Note that only a risk gradient can be
estimated using a design that use post-exposure time only, such as those illustrated in figure 1 (b) and (d).
It is necessary to assume that the risk returns to baseline in the post-exposure control period for the relative
incidence to retain the same definition.
SCCS
SCCS
post
exposure
SCRI two
reference
windows
SCRI one
reference
window
exposure
risk
risk
risk
risk
age group 1 age group 2 age group 3 age group 4
age group 2 age group 3 age group 4
ref ref
ref
(a)
(b)
(c)
(d)
start end
washout
washout
Figure 1 Example time lines for standard SCCS and SCRI designs with one exposure. The exposure
risk window is labelled ‘risk’ and washout window is labelled ‘washout’. Panel (a) SCCS with observation
period defined by age boundaries and four age groups. Panel (b) SCCS with observation period starting
at exposure. Panel (c) SCRI with two reference windows (labelled ‘ref’) either side of the exposure risk
window. Panel (d) SCRI with one reference window after the exposure risk window.
2.3 Bias related to non-recurrent outcomes
It is assumed that outcomes arise according to a non-homogeneous Poisson process. Under any standard
SCCS model (including SCRI), the Poisson rate is assumed to be constant within each window of time
defined by age and exposure categories. Outcomes are counts within each time window. Naturally, such a
model allows outcomes to be recurrent, but outcomesmust arise in time independently of one another. Such
independence is frequently not present in practice, for example the timing of a secondmyocardial infarction
will often not be independent of the timing of the first myocardial infarction. A simple work-around is to
include only first outcomes in a study. In considering how bias arises it is conceptually easier to think of a
non-recurrent outcome as the first of a potentially recurrent outcome, even if recurrence is impossible. The
shape of the distribution of first outcomes over age or time will be shifted toward lower ages or earlier dates
in the observation period than the distribution of all outcomes. In other words, if second and subsequent
outcomes are omitted, an increasing deficit of outcomes is created as time progresses. If this shift in
temporal distribution of common outcomes is not (or insufficiently) taken into account, estimates of the
exposure-related relative incidence may become biased. The extent of the bias will depend heavily upon
the distribution of exposures throughout observation periods. Where exposures tend to come toward the
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beginning of observation, exposures will coincide more often with first outcomes and the estimates of the
exposure-related relative incidence exp(βk) may become biased upward. Conversely, where exposures
tend to come toward the end of observation, estimates of exp(βk) may become biased toward 0. Little or
no bias should result when the probability of exposure is roughly constant throughout observation periods,
or when there is an equal distribution of reference time either side of an exposure risk window. Thus,
any SCCS design set-up where observation starts with a single exposure represents an extreme where the
potential for upward bias in exp(βk) is maximised (i.e. for no other SCCS design set up can bias be
greater). Whereas little or no bias should be present for an SCRI design with two reference windows of
equal length either side of the exposure risk window.
3 Analytic evaluation for a simple scenario
The rare outcome assumption cannot be investigated from case series data alone: it requires external infor-
mation. Such information is usually not difficult to obtain, especially since the precise disease frequency is
not required. However, it helps to know what is meant by ‘rare’ in this context. To this end, we undertake
some calculations in a special, but extreme, scenario.
Assume that the outcome hazard λ is constant and that outcome times T are exponentially distributed,
T ∼ M(λ). Suppose that the observation period is (0, b] and that there is a single exposure risk window
(c, c+ d] of length d with 0 ≤ c ≤ b− d. We investigate the asymptotic (large sample) bias in the relative
incidence ρ associated with this exposure risk window, in an SCCS analysis that makes no allowance for
age. Including age effects would be expected to reduce the bias in ρ. Note that investigating large sample
bias allows us to distinguish systematic bias relating to unique outcomes from bias relating to small samples
(Musonda et al., 2008).
Let Λ denote the cumulative incidence over the entire observation period (0, b], including the effect of
exposure. Thus,
Λ = ρλd+ λ(b − d).
The probability that an outcome occurs in the exposure risk window (c, c+ d], conditional on it occurring
in (0, b], is
P1 = P (c < T ≤ c+ d|T ≤ b) =
exp(−λc)(1 − exp(−ρλd))
1− exp(−Λ)
.
Similarly, the conditional probability that an outcome does not occur in the exposure risk window is
P0 = P (T ≤ c or T ≥ c+d|T ≤ b) =
1− exp(−λ(b − d)− ρλd)− exp(−λc)(1 − exp(−ρλd))
1− exp(−Λ)
.
The likelihood for an SCCS model with common observation period (0, b], common exposure risk window
(c, c + d] and no age effects is binomial. If N is the total number of cases (and therefore of unique
outcomes),N1 is the number of outcomes in the exposure risk window, andN0 the number of outcomes in
the reference windows, then the maximum likelihood estimator of ρ is
ρˆ =
N1
N0
×
b− d
d
.
Asymptotically as N →∞,
ρˆ→ ρ¯ =
P1
P0
×
b − d
d
in probability.
c© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
6 Whitaker et al.: Self-controlled case series studies with common non-recurrent outcomes.
We consider the limit in which λ, and hence Λ, are small. Using standard Taylor approximations,
ρ¯ =
exp(−λc)(1 − exp(−ρλd))
1− exp(−λ(b − d)− ρλd)− exp(−λc)(1 − exp(−ρλd))
×
b− d
d
≃
(1 − λc)[ρλd− 1
2
(ρλd)2]
λ(b − d) + ρλd− 1
2
[λ(b − d) + ρλd]2 − (1 − λc)[ρλd− 1
2
(ρλd)2]
×
b− d
d
≃ ρ(1 − λc)(1 −
1
2
ρλd)[1 +
1
2
λ(b − d) + ρλd− ρλ
dc
b − d
]
≃ ρ[1 +
1
2
Λ(1− 2
c
b− d
)],
to first order in Λ. Thus, the relative bias is of orderΛ/2 if c = 0,−Λ/2 if c = b−d, and 0 if c = (b−d)/2.
To put this in context, recall subsection 2.3; if outcome events arise according to a non-homogeneous
Poisson process and unique outcomes are thought of as the first event only, an excess of outcomes will
occur in exposure risk windows that fall at the beginning of the observation period (c = 0) resulting
in upward bias, which is of order Λ/2. Vice versa, there will be a dearth of outcomes in exposure risk
windows that fall at the end of the observation period (c = b− d) resulting in downward bias, which is of
order −Λ/2. In general, to first order,
|
ρ¯− ρ
ρ
| ≤
1
2
Λ.
Thus the relative bias in this setting is at most 1
2
Λ in absolute value.
For example, if the cumulative incidence over the observation period is about 0.1, the relative bias is of
the order of 5% or less. The additional inclusion of age effects will correct this bias to some degree, by
allowing for the shift in age effects produced by the absence of second or subsequent outcome events.
4 Simulations
Simulation choices using a single exposure risk period were made to demonstrate minimal, intermediate
and maximal bias when applying SCCS and SCRI models to the first of multiple outcomes.
4.1 Method
A study period was fixed at (0, 100] days for 1000 individuals i = 1, ..., 1000. The start of the exposure
risk period ci for individual was simulated within the period (0, 90] days and had fixed length 10 days, so
exposure risk periods were (ci, ci+10]. Exposure status is denoted k = 1 inside the exposure risk window
and k = 0 otherwise. Two scenarios for the distribution of exposure starts were explored, uniformly dis-
tributed throughout the observation period (to produce no bias using a standard SCCS approach) and linear
decreasing over the observation period (to produce some bias using a standard SCCS approach). SCRI ref-
erence windows were fixed at (max(0, ci−10), ci] (before exposure) and (ci+10,min(ci+20, 100)] (after
exposure), within the study period boundaries. Four age groups j = 1, 2, 3, 4 of length 25 days were fixed.
For each individual, nine boundaries at 0, (max(0, ci− 10), ci], (ci, ci +10], (ci +10,min(ci +20, 100)],
25, 50, 75 and 100 were ordered to form eight segments, indexed ijk, of length eijk ≥ 0. Segments
are illustrated in figure 2. Scenarios were simulated for three true exposure-related relative incidences
exp(β1), either exp(β1) = 1, 2, 5 (always with exp(β0) = 1). No effect of age was simulated, the true
age-related relative incidence for multiple outcomes exp(αj) = 1, j = 1, 2, 3, 4. Let Λ denote the cu-
mulative outcome rate over the entire observation period, excluding the effect of exposure (note that this
differs from section 3 in which Λ included the effect of exposure). Scenarios were simulated with six
choices of outcome rate Λ = 0.02, 0.05, 0.1, 0.2, 0.5, 1. An outcome hazard was determined for each seg-
ment λijk = eijk × Λ/100× exp(βk) and an overall outcome count simulated nijk ∼ Poisson(λijk). If
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Σinijk = 0 for an individual, outcomes were re-simulated for that individual; this was repeated until all
1000 individuals had least one outcomeΣinijk ≥ 1. The segment during which the first outcome occurred
was identified.
risk, k=1
SCCS age group 1 SCCS age group 2 SCCS age group 3 SCCS age group 4
SCRI ref SCRI ref
ci c+10i c+20ic-10i
0 25 50 75 100
Figure 2 Segments for an example simulated individual. The exposure risk window k = 1 is represented
by the black window, outside this window k = 0.
Segments were then restricted and/or combined to fit six models to the simulated data on each of the
recurrent outcome counts and first outcomes only (12 models total). The six models were: SCCS over
the full study period (0, 100] both with no age effect and with 4 age groups, SCCS starting from exposure
(ci, 100] both with no age effect and with 4 age groups, SCRI with two reference windows either side
of the exposure risk window (ci − 10, ci + 20] and SCRI with one reference window after the exposure
risk window (ci, ci+20]. Only SCCS models over the full study period included all 1000 simulated cases.
Restrictions on the observation periods for other models resulted in the exclusion of cases outside the given
boundaries.
Simulations were carried out using R, and models were fitted by conditional Poisson regression using
the package gnm (Turner and Firth, 2015). Simulations were replicated 5000 times. A relative bias was
calculated as
relative bias =
| exp(mean βˆ)− exp(true β)|
exp(true βˆ)
.
4.2 Results
Simulation results (mean βˆ) for the six models applied to first outcomes only and linear decreasing expo-
sure start times over the observation period are shown in Table 1. Results for the same model applied to all
outcomes is available in the supporting information, all displayed very little bias. Table 2 contains mean
relative biases for the same scenario, along with an approximate cumulative incidence for each model.
When reference periods are included both before and after exposure, SCCS with no age effect becomes
increasingly biased as the baseline cumulative outcome rate increases. Bias in the SCCS model is greatly
reduced by the inclusion of age effects. As expected, the SCRI model with two reference windows either
side of the exposure risk window showed very little bias.
As expected, bias was greater for the models with observation starting from exposure. The relative
bias should be approximately 1
2
Λ for post-exposure reference only models without age effects, and this
represents the maximum possible relative bias. From Table 2 it can be seen that simulation results are
roughly, albeit not exactly, in line with this. When no age effects were fitted in the SCCS model, bias
became very large when the cumulative outcome rate rose above 0.1. The simulation results demonstrate
that inclusion of age effects reduces bias considerably for the SCCS model, though where the baseline
outcome rate within an age group remains above 0.1, relative bias remains greater than 5%. The SCRI
model, with observation length of only 20 days, displays greater bias than the SCCS model with age groups
of length 25-days, though bias is considerably less than the SCCS model with no age effects. However, the
proportion of exposure risk time over the observation period is greater for the SCRI model, which pushes
up the overall cumulative outcome rate over the 20-day period relative to the average cumulative outcome
rate within a 25-day SCCS age group.
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Table 1 Simulation results, 5000 replications. Exposure start day linear decreasing over observation
period. Analyses of first outcomes only. Base rate is the baseline cumulative outcome rate over 100 days.
True β is the true natural logarithm of the relative incidence associated with the exposure risk window.
Results are the means of the estimated log relative incidences βˆ. ∗Starred results show> 5% relative bias.
Means of s.e.(βˆ) are also given.
reference before and after exposure post-exposure reference only
SCCS SCCS + age SCRI, 2 ref SCCS SCCS + age SCRI, 1 ref
base true β mean βˆ mean βˆ mean βˆ mean βˆ mean βˆ mean βˆ
rate (mean s.e.βˆ) (mean s.e.βˆ) (mean s.e.βˆ) (mean s.e.βˆ) (mean s.e.βˆ) (mean s.e.βˆ)
0.02 0.000 0.000(0.106) -0.004(0.107) 0.000(0.124) 0.004(0.110) -0.003(0.135) 0.005(0.142)
0.05 0.000 0.005(0.105) -0.003(0.107) -0.002(0.124) 0.015(0.110) 0.001(0.135) 0.005(0.142)
0.1 0.000 0.012(0.105) -0.004(0.107) -0.002(0.123) 0.031(0.109) 0.002(0.134) 0.007(0.141)
0.2 0.000 0.028(0.104) -0.004(0.106) -0.001(0.123) ∗0.069(0.109) 0.008(0.134) 0.021(0.141)
0.5 0.000 ∗0.071(0.103) -0.005(0.104) 0.001(0.120) ∗0.175(0.107) 0.023(0.133) ∗0.050(0.139)
1 0.000 ∗0.137(0.100) -0.007(0.102) 0.002(0.117) ∗0.353(0.106) ∗0.053(0.133) ∗0.102(0.137)
0.02 0.693 0.694(0.082) 0.691(0.084) 0.693(0.107) 0.699(0.087) 0.695(0.117) 0.700(0.129)
0.05 0.693 0.700(0.082) 0.692(0.084) 0.696(0.106) 0.713(0.087) 0.699(0.117) 0.707(0.129)
0.1 0.693 0.710(0.082) 0.693(0.084) 0.697(0.106) ∗0.735(0.087) 0.706(0.117) 0.714(0.129)
0.2 0.693 0.725(0.081) 0.691(0.083) 0.694(0.105) ∗0.773(0.087) 0.713(0.117) 0.726(0.129)
0.5 0.693 ∗0.772(0.080) 0.691(0.082) 0.698(0.104) ∗0.897(0.087) ∗0.746(0.118) ∗0.772(0.128)
1 0.693 ∗0.840(0.078) 0.688(0.080) 0.699(0.101) ∗1.106(0.086) ∗0.803(0.119) ∗0.849(0.128)
0.02 1.609 1.615(0.066) 1.611(0.069) 1.614(0.101) 1.622(0.073) 1.617(0.111) 1.625(0.131)
0.05 1.609 1.620(0.066) 1.610(0.069) 1.614(0.101) 1.638(0.073) 1.627(0.111) 1.633(0.131)
0.1 1.609 1.633(0.066) 1.613(0.069) 1.616(0.101) 1.668(0.074) 1.636(0.111) 1.647(0.131)
0.2 1.609 1.651(0.066) 1.610(0.069) 1.614(0.100) ∗1.723(0.074) 1.662(0.112) 1.677(0.132)
0.5 1.609 ∗1.706(0.065) 1.609(0.068) 1.614(0.098) ∗1.899(0.076) ∗1.738(0.115) ∗1.770(0.135)
1 1.609 ∗1.762(0.065) 1.597(0.067) 1.598(0.096) ∗2.187(0.079) ∗1.867(0.123) ∗1.926(0.142)
The mean standard errors (s.e.) in the table reflect the number of cases and observation time included
in each analysis. Age effects will be estimated with much less precision for the SCCS analyses starting
observation with exposure, which affects the precision of the exposure estimates.
Simulation results with a uniform distribution of first exposure over the 100 day study period are given
in the supporting information. Results are similar, except that for the full SCCS model with reference
before and after exposure with no age effect, results are very close to unbiased, as expected.
4.3 Evaluation
For SCCS models, it appears to be key that the cumulative outcome rate over the observation period is less
than 0.1 to ensure bias is less than 5%, and that inclusion of age effects clearly reduces bias further. The
same rule of thumb appears to apply for the SCRI model with 1 reference, that the cumulative outcome
rate over all windows should be less than 0.1 to ensure relative bias below 5%. Bias is considerably less
for any bi-directional design choice, which should also apply for standard SCCS models where there are
multiple intermittent exposures.
The SCRI model with 2 equal length reference periods either side of the exposure risk window min-
imises bias due to common unique events by design and can sometimes be convenient in terms of data
collection. Potential disadvantages of SCRI over SCCS to be mindful of when designing a study are that
reference windows need to be carefully chosen, age or season effects if present will be more difficult to al-
low for, and reduced power, which not only depends on case sample size (as cases whose outcome occurred
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Table 2 Relative bias calculated from simulation results, 5000 replications. Exposure start day linear
decreasing over observation period. Analyses of first outcomes only. The column labelled ‘base rate’ gives
the baseline cumulative outcome rate over 100 days, not taking the exposure effect into account. Columns
labelled ‘approx Λ’ give an approximate cumulative incidence, this has been calculated for each of full
SCCS, SCRI with two reference windows, SCCS post exposure only and SCRI with one post exposure
reference only. Columns labelled ‘relative bias’ contain the mean relative bias defined at the end of section
4.1.
reference before and after exposure post-exposure reference only
SCCS SCRI (2 reference) SCCS SCRI (1 reference)
no age age no age age
base true β approx relative relative approx relative approx relative relative approx relative
rate Λ bias bias Λ bias Λ bias bias Λ bias
0.02 0.000 0.020 0.000 0.004 0.006 0.000 0.014 0.004 0.003 0.004 0.005
0.05 0.000 0.050 0.005 0.003 0.015 0.002 0.035 0.016 0.001 0.010 0.005
0.1 0.000 0.100 0.012 0.004 0.030 0.002 0.070 0.032 0.002 0.020 0.007
0.2 0.000 0.200 0.028 0.004 0.060 0.001 0.140 0.072 0.008 0.040 0.021
0.5 0.000 0.500 0.074 0.005 0.150 0.001 0.350 0.191 0.023 0.100 0.051
1 0.000 1.000 0.147 0.007 0.300 0.002 0.700 0.424 0.055 0.200 0.108
0.02 0.693 0.022 0.001 0.002 0.008 0.000 0.016 0.006 0.002 0.006 0.007
0.05 0.693 0.055 0.007 0.001 0.020 0.003 0.040 0.020 0.006 0.015 0.013
0.1 0.693 0.110 0.017 0.000 0.040 0.004 0.080 0.043 0.013 0.030 0.021
0.2 0.693 0.220 0.032 0.002 0.080 0.001 0.160 0.083 0.020 0.060 0.033
0.5 0.693 0.550 0.082 0.002 0.200 0.005 0.400 0.227 0.054 0.150 0.082
1 0.693 1.100 0.158 0.005 0.400 0.006 0.800 0.511 0.116 0.300 0.169
0.02 1.609 0.028 0.005 0.001 0.014 0.004 0.022 0.013 0.007 0.012 0.016
0.05 1.609 0.070 0.010 0.001 0.035 0.005 0.055 0.029 0.017 0.030 0.024
0.1 1.609 0.140 0.024 0.003 0.070 0.007 0.110 0.060 0.027 0.060 0.039
0.2 1.609 0.280 0.043 0.001 0.140 0.005 0.220 0.120 0.054 0.120 0.070
0.5 1.609 0.700 0.102 0.000 0.350 0.005 0.550 0.336 0.137 0.300 0.174
1 1.609 1.400 0.165 0.012 0.700 0.011 1.100 0.781 0.294 0.600 0.372
far in time from exposure are dropped), but also on the ratio of the length of exposure risk windows to ref-
erence windows (with optimal efficiency when the ratio of the total length of all exposure risk windows to
the total length of all reference windows is small). Further, use of defined reference windows in relation
to exposure rather than use of all available baseline time will in practice subtlety change interpretation
of results; relative incidences gained from a full SCCS analysis with baseline time both before and after
exposure should target the relative risk of a cohort study, whereas relative incidences gained from SCRI
models and SCCS including only reference time after exposure can be thought of as a risk gradient.
5 Examples
The information required to assess the potential for bias relating to unique events are incidence rates in the
study population. Unfortunately, this cannot be quantified from a case series alone. Sometimes information
on a full cohort will be available, but where it is not, information on incidence rates is readily available in
the literature and a rough idea of cumulative incidence should be sufficient to assess the potential for bias
relating to unique events.
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5.1 Febrile convulsions at ages 0-24 months
Febrile convulsions after childhood vaccinations have been studied using SCCS (Weldeselassie et al., 2011;
Hanf et al., 2013; Huang et al., 2010). Most studies have included recurrent convulsions, such as Hanf et
al. (2013) in a study with mumps, measles, rubella (MMR) vaccination as the exposure; re-admissions
within 72 hours were counted as the same episode. Observation periods span the period during which
vaccinations are normally given. For example, MMR is often given during the second year of life, so Hanf
et al. (2013) included children between 240 and 730 days of age. Diphtheria-tetanus-acellular pertussis
(DTaP) is given during the first two years of life, so Huang et al. (2010) included children aged 6 weeks
to 23 months. There is a strong age trend in febrile convulsions, with incidence peaking during the second
year of life, so studies include age in the SCCS model.
A British cohort study followed 13,135 children from birth to age 5 (Verity et al., 1985). Excluding 13
children with a prior condition and 97 with missing information, it was estimated that 197 children expe-
rienced a febrile convulsion before the age of 2 years, of which 82 experienced more than one convulsion
at some point before the age of 5 years. Exact numbers of total febrile convulsions by age are not given,
but assuming that all recurrences occurred before age 2 (so as to over-estimate incidence), the cumulative
incidence of first and recurrent convulsions is approximately 0.034 for the first two years of life. This is
under 0.05, febrile convulsions are sufficiently rare such that little or no bias should be present in studies
of first events only (most studies include multiple events).
5.2 Myocardial infarction
SCCS has been used to study the association between prescriptionmedicines and first myocardial infarction
(Gault et al., 2017). For example, Wong et al. (2016) studied cardiovascular outcomes associated with use
of clarithromycin. The study period spanned 10 years from 2003 to 2012, and included age bands of length
1 year. Thus, observation periods can be relatively long.
ARIC surveillance (USA) provide data on the number of coronary events per year per 1000 persons in
the population, by age, race and sex (Benjamin et al., 2017). Events are defined as definite or probable
myocardial infarctions (new or recurrent) and definite coronary heart disease deaths. The average incidence
of events is highest for black males aged 75-84 years, at approximately 19 per year per 1000 persons for
the period 2005-2013. The cumulative incidence over, say, 10 years, for an individual in this group would
be 0.19. Depending on design choices, two or more age bands (of length 5 years or less) may be needed in
an SCCS study to ensure relative bias is less than 5%. However, populations studied are likely to be mixed
in terms of age, sex and race, and overall cumulative incidence will likely be lower. For example, average
incidence of events at ages 55-64 is reported to be between 2 and 8 per year per 1000 persons depending
on race and sex, thus cumulative incidence over 10 years for this age group is clearly less than 0.1.
5.3 Death within population of opioid drug abusers
SCCS methods have recently been applied to all cause mortality amongst drug abusers being treated in UK
primary care (Steer et al. , 2018).
In total, 11,033 patients were identified who had received methadone or buprenorphine treatment for
opioid drug abuse between 1998 and 2014. For this cohort, the average time of follow-up was 2.76 years
with 587 deaths being observed. This suggested an overall incidence rate per patient of 0.053. The analyses
adjusted for age (roughly using age bands of length 10 years, which were constant within many individ-
uals with shorter observation periods), calendar year and an index of comorbidity based upon 17 chronic
illnesses (which could vary with time).
Much care was taken to reduce bias in analyses by use of extended SCCS methods for death outcomes
(Farrington et al., 2009; Kuhnert et al., 2011) with additional modification of the treatment end during
the planned follow-up period. However, these extended methods use post-exposure time only to estimate
exposure-related effects, which should maximise systematic bias relating to unique outcomes.
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Within this cohort of drug abusers, it was observed that death is more commonwithin certain population
subgroups. For example, for age, the incidence rate rose to 0.176 for those patients aged 50+ years while,
for comorbidity, the incidence rate was 0.439 for the highest category.
6 Final remarks
We have offered some guidance about how rare a rare unique adverse health outcome is required to be in
order that relative bias is less than about 5%, or that relative bias should be to the order of no more than 1
2
Λ,
where Λ is the cumulative incidence over the entire observation period. We acknowledge that our choice
of 5% here is arbitrary, and that what is acceptable within a particular epidemiological study setting may
vary. However, it may be useful to acknowledge the potential for bias in SCCS studies of non-rare unique
outcomes, particularly when results are borderline statistically significant. Evaluation of the potential order
of bias can be approximate, using information external to a study if necessary. In our examples, we saw
that incidence rates vary between subgroups based on age, ethnicity and comorbidity. We acknowledge that
it is a limitation of this work that differing incidence between subgroups has not been evaluated, although
we believe that a rough assessment can be based upon average incidence over observation periods.
The direction of bias due to common unique outcomes is fairly predictable, with upward bias created
when exposures tend to fall toward the beginning of observation and downward bias when exposures tend
to fall toward the end of observation periods. Regardless of how common unique outcomes are, little bias
will arise when exposures are randomly scattered throughout, or fall toward the middle of observation
periods.
Our findings highlight the importance of including age (and/or calendar time) effects in SCCS studies.
This is particularly important for non-rare unique outcomes to allow for the shift in age effects produced by
the absence of second or subsequent outcome events that would be present according the assumption that
events arise according to a non-homogeneous Poisson process. When unique outcomes are not rare, fine
control of age effects is preferable. This can be achieved by including sufficiently narrow age categories,
or by modelling age effects using splines, fractional polynomials or the semi-parametric SCCS model
(Ghebremichael-Weldeselassie et al., 2014; Lee and Carlin, 2014; Farrington and Whitaker, 2006). Note
that sample size plays no role in bias related to common unique events, but increasing sample size can help
estimates age effects more reliably. Age is frequently ignored in SCRI studies under the assumption that
incidence changes very little over the time observed. Study of common unique outcomes coupled with the
use of only one reference window may give reason to take age effects into account, and Li et al. (2015)
outline some strategies for controlling for age in SCRI studies, by either including unexposed cases or by
using external information on outcome incidence rates.
There are several potential sources of bias that researchers should be mindful of when conducting SCCS
or SCRI studies, including time-varying confounders, small sample estimation bias (Musonda et al., 2008),
systematic bias resulting from outcomes that prohibit or precipitate subsequent exposure (Farrington et al.,
2009; Kuhnert et al., 2011), systematic bias resulting from outcomes that censor subsequent observation
(Farrington et al., 2011), and bias resulting from outcomes that reasonably do not arise according to a non-
homogeneousPoisson process (Simpson , 2013), which includes common unique outcomes. Outcomes that
potentially censor the observation period, such as myocardial infarction or stroke that carry high mortality
risk, have not been mentioned in the present paper, but similar to bias relating to unique common outcomes,
the magnitude and direction of bias depends on the distribution of exposure risk windows over observation
periods. Simple sensitivity analyses can be carried out to check whether results are robust to such bias
(Whitaker et al., 2018). In our experience, bias resulting from outcomes that permanently prohibit or
precipitate subsequent exposure is the most problematic and where such an issue is present, use of an SCCS
design that circumvents it is necessary. However, SCCS models that begin observation from exposure
maximise bias relating to non-rare unique outcomes, and this includes the modified SCCS models outlined
in Farrington et al. (2009) and Kuhnert et al. (2011) for outcomes that prohibit subsequent exposure.
c© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
12 Whitaker et al.: Self-controlled case series studies with common non-recurrent outcomes.
Outcomes that can be studied using such SCCS models include death (Petersen et al., 2016), and we have
demonstrated that death can be relatively common within certain population subgroups. To reiterate, use
of these models that use observation time from exposure forwards is essential to reduce bias relating to
the assumption that outcomes must not influence subsequent exposure, and any bias relating to common
unique non-recurrent outcomes is likely to be small in comparison with this.
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